Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Grisham

Showing results (801-810 of 834) with videos related to

Pageof 84
Sort By:
Contemporary Clinical Trials|January 19, 2026
Expanding access to cancer genetic care for cancer survivors: Rationale and design for a randomized controlled trial of a chatbot-based genetic education and testingJinghua An, Maisha Huq, Erin Speiser, et al.
Biorxiv : the Preprint Server for Biology|February 17, 2023
A "Four Core Genotypes" rat model to distinguish mechanisms underlying sex-biased phenotypes and diseasesArthur P Arnold, Xuqi Chen, Michael N Grzybowski, et al.
Gynecologic Oncology|November 1, 2025
A pilot study of nivolumab in combination with neoadjuvant and post-surgical chemotherapy in newly diagnosed ovarian cancerSara Moufarrij, Claire F Friedman, Samuel Freeman, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 17, 2023
Low-grade serous ovarian cancer: expert consensus report on the state of the scienceRachel N Grisham, Brian M Slomovitz, Nicole Andrews, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2024
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial CancerAngela K Green, Qin Zhou, Alexia Iasonos, et al.
JCO Precision Oncology|September 14, 2020
<i>BRCA</i> Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian CancerYing L Liu, Pier Selenica, Qin Zhou, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trialDmitriy Zamarin, Sven Walderich, Aliya Holland, et al.
Gynecologic Oncology|January 20, 2023
Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide managementYing L Liu, Beryl L Manning-Geist, Andrea Knezevic, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 7, 2024
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancerRachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen, et al.
Gynecologic Oncology|April 25, 2025
Mesonephric-like adenocarcinoma of the female genital tract: Pathologic diagnosis, clinical outcomes, and novel therapeuticsKari L Ring, Anne M Mills, Brooke E Howitt, et al.
Pageof 84

Showing results (801-810 of 834) with videos related to

Sort By:
Pageof 84
Contemporary Clinical Trials|January 19, 2026
Expanding access to cancer genetic care for cancer survivors: Rationale and design for a randomized controlled trial of a chatbot-based genetic education and testingJinghua An, Maisha Huq, Erin Speiser, et al.
Biorxiv : the Preprint Server for Biology|February 17, 2023
A "Four Core Genotypes" rat model to distinguish mechanisms underlying sex-biased phenotypes and diseasesArthur P Arnold, Xuqi Chen, Michael N Grzybowski, et al.
Gynecologic Oncology|November 1, 2025
A pilot study of nivolumab in combination with neoadjuvant and post-surgical chemotherapy in newly diagnosed ovarian cancerSara Moufarrij, Claire F Friedman, Samuel Freeman, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 17, 2023
Low-grade serous ovarian cancer: expert consensus report on the state of the scienceRachel N Grisham, Brian M Slomovitz, Nicole Andrews, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2024
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial CancerAngela K Green, Qin Zhou, Alexia Iasonos, et al.
JCO Precision Oncology|September 14, 2020
<i>BRCA</i> Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian CancerYing L Liu, Pier Selenica, Qin Zhou, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trialDmitriy Zamarin, Sven Walderich, Aliya Holland, et al.
Gynecologic Oncology|January 20, 2023
Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide managementYing L Liu, Beryl L Manning-Geist, Andrea Knezevic, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 7, 2024
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancerRachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen, et al.
Gynecologic Oncology|April 25, 2025
Mesonephric-like adenocarcinoma of the female genital tract: Pathologic diagnosis, clinical outcomes, and novel therapeuticsKari L Ring, Anne M Mills, Brooke E Howitt, et al.
Pageof 84